Literature DB >> 28637928

The long noncoding RNA Wisper controls cardiac fibrosis and remodeling.

Rudi Micheletti1, Isabelle Plaisance1, Brian J Abraham2, Alexandre Sarre3, Ching-Chia Ting1, Michael Alexanian1, Daniel Maric1, Damien Maison1, Mohamed Nemir1, Richard A Young2,4, Blanche Schroen5, Arantxa González6,7, Samir Ounzain8, Thierry Pedrazzini8.   

Abstract

Long noncoding RNAs (lncRNAs) are emerging as powerful regulators of cardiac development and disease. However, our understanding of the importance of these molecules in cardiac fibrosis is limited. Using an integrated genomic screen, we identified Wisper (Wisp2 super-enhancer-associated RNA) as a cardiac fibroblast-enriched lncRNA that regulates cardiac fibrosis after injury. Wisper expression was correlated with cardiac fibrosis both in a murine model of myocardial infarction (MI) and in heart tissue from human patients suffering from aortic stenosis. Loss-of-function approaches in vitro using modified antisense oligonucleotides (ASOs) demonstrated that Wisper is a specific regulator of cardiac fibroblast proliferation, migration, and survival. Accordingly, ASO-mediated silencing of Wisper in vivo attenuated MI-induced fibrosis and cardiac dysfunction. Functionally, Wisper regulates cardiac fibroblast gene expression programs critical for cell identity, extracellular matrix deposition, proliferation, and survival. In addition, its association with TIA1-related protein allows it to control the expression of a profibrotic form of lysyl hydroxylase 2, implicated in collagen cross-linking and stabilization of the matrix. Together, our findings identify Wisper as a cardiac fibroblast-enriched super-enhancer-associated lncRNA that represents an attractive therapeutic target to reduce the pathological development of cardiac fibrosis in response to MI and prevent adverse remodeling in the damaged heart.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28637928      PMCID: PMC5643582          DOI: 10.1126/scitranslmed.aai9118

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  64 in total

1.  TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs.

Authors:  C Le Guiner; F Lejeune; D Galiana; L Kister; R Breathnach; J Stévenin; F Del Gatto-Konczak
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

Review 2.  The promise of enhancer-associated long noncoding RNAs in cardiac regeneration.

Authors:  Samir Ounzain; Thierry Pedrazzini
Journal:  Trends Cardiovasc Med       Date:  2015-02-07       Impact factor: 6.677

3.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

Review 4.  "Cat's Cradling" the 3D Genome by the Act of LncRNA Transcription.

Authors:  Marta Melé; John L Rinn
Journal:  Mol Cell       Date:  2016-06-02       Impact factor: 17.970

5.  Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development.

Authors:  Y Blech-Hermoni; S J Stillwagon; A N Ladd
Journal:  Dev Dyn       Date:  2013-04-15       Impact factor: 3.780

6.  Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs.

Authors:  Samir Ounzain; Rudi Micheletti; Tal Beckmann; Blanche Schroen; Michael Alexanian; Iole Pezzuto; Stefania Crippa; Mohamed Nemir; Alexandre Sarre; Rory Johnson; Jérôme Dauvillier; Frédéric Burdet; Mark Ibberson; Roderic Guigó; Ioannis Xenarios; Stephane Heymans; Thierry Pedrazzini
Journal:  Eur Heart J       Date:  2014-04-30       Impact factor: 29.983

7.  Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease.

Authors:  Samir Ounzain; Iole Pezzuto; Rudi Micheletti; Frédéric Burdet; Razan Sheta; Mohamed Nemir; Christine Gonzales; Alexandre Sarre; Michael Alexanian; Matthew J Blow; Dalit May; Rory Johnson; Jérôme Dauvillier; Len A Pennacchio; Thierry Pedrazzini
Journal:  J Mol Cell Cardiol       Date:  2014-08-19       Impact factor: 5.000

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

10.  MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response.

Authors:  Jennifer Davis; Nathan Salomonis; Natasha Ghearing; Suh-Chin J Lin; Jennifer Q Kwong; Apoorva Mohan; Maurice S Swanson; Jeffery D Molkentin
Journal:  Nat Commun       Date:  2015-12-16       Impact factor: 14.919

View more
  93 in total

Review 1.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

2.  The Cardiac Myofibroblast.

Authors:  Michael Alexanian; Saptarsi M Haldar
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

Review 3.  The circulating non-coding RNA landscape for biomarker research: lessons and prospects from cardiovascular diseases.

Authors:  Stępień E; Marina C Costa; Szczepan Kurc; Anna Drożdż; Nuno Cortez-Dias; Francisco J Enguita
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

Review 4.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 5.  Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

Authors:  Sébastien Bonnet; Olivier Boucherat; Roxane Paulin; Danchen Wu; Charles C T Hindmarch; Stephen L Archer; Rui Song; Joseph B Moore; Steeve Provencher; Lubo Zhang; Shizuka Uchida
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-04       Impact factor: 4.249

6.  Distinct roles of myofibroblast-specific Smad2 and Smad3 signaling in repair and remodeling of the infarcted heart.

Authors:  Shuaibo Huang; Bijun Chen; Ya Su; Linda Alex; Claudio Humeres; Arti V Shinde; Simon J Conway; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2019-05-11       Impact factor: 5.000

Review 7.  Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine.

Authors:  Lilian Grigorian Shamagian; Rosalinda Madonna; Doris Taylor; Andreu M Climent; Felipe Prosper; Luis Bras-Rosario; Antoni Bayes-Genis; Péter Ferdinandy; Francisco Fernández-Avilés; Juan Carlos Izpisua Belmonte; Valentin Fuster; Roberto Bolli
Journal:  Circ Res       Date:  2019-03-15       Impact factor: 17.367

8.  Epigenetic therapies in heart failure.

Authors:  Michael Alexanian; Arun Padmanabhan; Timothy A McKinsey; Saptarsi M Haldar
Journal:  J Mol Cell Cardiol       Date:  2019-04-13       Impact factor: 5.000

Review 9.  Long Noncoding RNAs in Atherosclerosis and Vascular Injury: Pathobiology, Biomarkers, and Targets for Therapy.

Authors:  Jacob B Pierce; Mark W Feinberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-07-23       Impact factor: 8.311

Review 10.  Anti-fibrotic effects of curcumin and some of its analogues in the heart.

Authors:  Armita Mahdavi Gorabi; Saeideh Hajighasemi; Nasim Kiaie; Giuseppe M C Rosano; Thozhukat Sathyapalan; Khalid Al-Rasadi; Amirhossein Sahebkar
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.